<!DOCTYPE html>
<html>
  <head>
    <title>oral anticoagulation</title>
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <meta charset="utf-8">
    <!-- Bootstrap -->
    <link href="//netdna.bootstrapcdn.com/bootswatch/3.2.0/flatly/bootstrap.min.css" rel="stylesheet" media="screen">
    <link href="/css/site.css" rel="stylesheet" media="screen">
    <link href="/css/syntax.css" rel="stylesheet" media="screen">

    <!-- HTML5 Shim and Respond.js IE8 support of HTML5 elements and media queries -->
    <!-- WARNING: Respond.js doesn't work if you view the page via file:// -->
    <!--[if lt IE 9]>
      <script src="https://oss.maxcdn.com/libs/html5shiv/3.7.0/html5shiv.js"></script>
      <script src="https://oss.maxcdn.com/libs/respond.js/1.3.0/respond.min.js"></script>
    <![endif]-->
<script>
  (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
  (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
  m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
  })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

  ga('create', 'UA-48968311-4', 'jandecaluwe.com');
  ga('send', 'pageview');

</script>
  </head>

  <body>

    <!-- Fixed navbar -->
    <div class="navbar navbar-default navbar-fixed-top">
      <div class="container">
        <div class="navbar-header">
          <button type="button" class="navbar-toggle" data-toggle="collapse" data-target=".navbar-collapse">
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
          </button>
          <a class="navbar-brand" href="/">Rory’s notes</a>
        </div>
        <div class="navbar-collapse collapse">

          <ul class="nav navbar-nav navbar-left">
 
          </ul>

          <ul class="nav navbar-nav navbar-right">
            <li class="active"><a href="/notes/">notes</a></li>
          </ul>

        </div><!--/.nav-collapse -->
      </div>
    </div>


<div class="container">

  <ol class="breadcrumb">
    <li><a href="/">Home</a></li>
      <li><a href="/notes/">notes</a></li>
      <li><a href="/notes/haematology/">haematology</a></li>
      <li class="active">oral anticoagulation</li>
  </ol>

  <div class="page-header">
 
    <h1>oral anticoagulation</h1>
  </div>

  <div class="row">

    <div class="col-md-3" role="navigation"> 
 
      <div class="sidebar" data-spy="affix" data-offset-top="80" data-offset-bottom="60">
        <div class="well">
          <a href="#"><strong>oral anticoagulation</strong></a>
          <div class="toc">
<ul>
<li><a href="#warfarin">Warfarin</a><ul>
<li><a href="#monitoring">Monitoring</a></li>
<li><a href="#managing-warfarin-treatment">Managing warfarin treatment</a></li>
<li><a href="#drug-interactions">Drug interactions</a></li>
<li><a href="#bleeding-risk">bleeding risk</a></li>
<li><a href="#over-anti-coagulation">over anti-coagulation:</a></li>
</ul>
</li>
<li><a href="#dabigatran">Dabigatran</a><ul>
<li><a href="#indications">Indications</a></li>
<li><a href="#dosing">Dosing</a></li>
<li><a href="#advantages-over-warfarin">advantages over warfarin</a></li>
<li><a href="#initiating">initiating</a></li>
<li><a href="#monitoring_1">Monitoring</a></li>
<li><a href="#adverse-effects">Adverse effects</a></li>
</ul>
</li>
</ul>
</div>

        </div>
      </div>
    </div>
 
    <div class="content">
      <div class="col-md-6" role="main">
        <h3 id="warfarin">Warfarin</h3>
<h4 id="monitoring">Monitoring</h4>
<ul>
<li>
<p>INR</p>
<ul>
<li>
<p>documented in clincial notes</p>
<ul>
<li>
<p>on warfarin</p>
</li>
<li>
<p>condition for which warfarin has been prescribed</p>
</li>
<li>
<p>target INR range</p>
</li>
<li>
<p>planned duration of treatmnet</p>
</li>
<li>
<p>brand of warfarin</p>
</li>
</ul>
</li>
</ul>
</li>
</ul>
<h4 id="managing-warfarin-treatment">Managing warfarin treatment</h4>
<ul>
<li>
<p>risk of bleeding greatest who have not received warfarin and in first 3 months</p>
</li>
<li>
<p>Any patient on warfarin should be aware of risks and early warning signs of bleeding</p>
<ul>
<li>followed closely to ensure INR not >3</li>
</ul>
</li>
<li>
<p>for most people testing every 2,4,6,8 weekly depending</p>
</li>
<li>
<p>target = 2.5 for most (2-3)</p>
<ul>
<li>
<p>prophlaxis/treatment VTE</p>
</li>
<li>
<p>AF</p>
</li>
<li>
<p>valvular heart disease</p>
</li>
<li>
<p>(mechanical valve dependent of type of valve)</p>
</li>
</ul>
</li>
<li>
<p>duration = 13 wks for provoked DVT or PE</p>
</li>
<li>
<p>unprovoked = 13wk but indefinite use may be appropriate</p>
</li>
<li>
<p>AF, cardiomyopathy, valvular heard disease = indefinite</p>
</li>
<li>
<p>changes in INR</p>
<ul>
<li>
<p>major changes in diet or etoh</p>
<ul>
<li>consistent proportion of vit K rich food(brocooli, spinach, cabbage)</li>
</ul>
</li>
<li>
<p>drug interactoins</p>
<ul>
<li>plus interactions that don’t change INR and increase risk of bleeding; NSAIDS, aspriin, ssri</li>
</ul>
</li>
<li>
<p>systemic or concurrent illness</p>
<ul>
<li>
<p>CHF</p>
<ul>
<li>hepatic congestion</li>
</ul>
</li>
<li>
<p>hypothyroidism</p>
<ul>
<li>decrease catabolism of vit K clotting factors</li>
</ul>
</li>
<li>
<p>hyperthyroidism</p>
<ul>
<li>increase catabolism of vit k clotting factors</li>
</ul>
</li>
<li>
<p>liver failure</p>
</li>
</ul>
</li>
<li>
<p>non-adherence to dosage regime</p>
<ul>
<li>change in INR 2-5d after missed dose</li>
</ul>
</li>
<li>
<p>unknown</p>
</li>
</ul>
</li>
<li>
<p>computerised decision support > human</p>
<ul>
<li>
<p>better control</p>
</li>
<li>
<p>fewer tests</p>
</li>
</ul>
</li>
<li>
<p>stop antiplatelets if starting warfarin for anything other than complicated ACSwhere clopidogrel/aspriin short term may be useful in those with low bleeding risk</p>
</li>
</ul>
<h4 id="drug-interactions">Drug interactions</h4>
<p>Inhibit: increase risk of bleeding</p>
<ul>
<li>
<p>Antibiotics</p>
<ul>
<li>
<p>most</p>
</li>
<li>
<p>macrolides</p>
</li>
<li>
<p>metronidazole</p>
</li>
<li>
<p>quinolones</p>
</li>
<li>
<p>cotrimoxazole</p>
</li>
</ul>
</li>
<li>
<p>antifungazole</p>
<ul>
<li>
<p>fluconazole, miconazole</p>
<ul>
<li>including gel and vaginal preparations</li>
</ul>
</li>
</ul>
</li>
<li>
<p>SSRI</p>
<ul>
<li>
<p>inhibit with platelet function</p>
<ul>
<li>increase risk without change INR</li>
</ul>
</li>
<li>
<p>fluoxetine also inhibit warfarin metabolism</p>
</li>
</ul>
</li>
<li>
<p>Antiplatelet</p>
<ul>
<li>
<p>aspirin, clopidogrel, dipyridamole</p>
<ul>
<li>interfere priamry haemostasis</li>
</ul>
</li>
</ul>
</li>
<li>
<p>Amiodarone</p>
</li>
<li>
<p>NSAIDS</p>
<ul>
<li>direct mucozal injury</li>
</ul>
</li>
<li>
<p>Paracetamol</p>
<ul>
<li>
<p>direct interference with Vit K cycle</p>
</li>
<li>
<p>unlikely with short term use</p>
</li>
</ul>
</li>
</ul>
<p>Induction - increased thromboisis</p>
<ul>
<li>
<p>rifampicin</p>
</li>
<li>
<p>St John’s wort</p>
</li>
<li>
<p>foods with high vit K content</p>
</li>
</ul>
<h4 id="bleeding-risk">bleeding risk</h4>
<ul>
<li>
<p>concomitant use of aspirin</p>
</li>
<li>
<p>polypharmacy - 7 or more medications</p>
</li>
<li>
<p>other comorbidities</p>
</li>
<li>
<p>rate of spontaneous intracranial haemorrhage >70yo = 0.15%</p>
</li>
<li>
<p>BAFTA = significantly lower risk of stroke, intracranial haemorrhage or arterial embolism but same risk of bleeding as aspirin</p>
</li>
<li>
<p>HAS BLED = ≥ 3 = high risk of bleeding</p>
<ul>
<li>
<p>Hypertension (sbP >160)</p>
</li>
<li>
<p>abnormal renal and liver function (1each)</p>
</li>
<li>
<p>stroke (1)</p>
</li>
<li>
<p>bleeding</p>
</li>
<li>
<p>labile INR</p>
</li>
<li>
<p>elderly >65</p>
</li>
<li>
<p>Drugs or etoh (1 each)</p>
</li>
<li>
<p>max = 9</p>
</li>
</ul>
</li>
</ul>
<h4 id="over-anti-coagulation">over anti-coagulation:</h4>
<ul>
<li>
<p>INR 5-9</p>
<ul>
<li>
<p>stop warfarin</p>
</li>
<li>
<p>test daily until therapeutic</p>
</li>
<li>
<p>restart wiht reduced dose when INR \&lt;5</p>
</li>
<li>
<p>Give vit K 1-2.5mg orally if INR fails to reduce or if high risk of serious bleeding</p>
</li>
</ul>
</li>
<li>
<p>INR >9 without bleeding</p>
<ul>
<li>
<p>stop</p>
</li>
<li>
<p>vit K 2.5-5mg orally</p>
</li>
<li>
<p>measure in 24hrs</p>
</li>
<li>
<p>restart at reduced dose when INR \&lt;5</p>
</li>
</ul>
</li>
<li>
<p>INR ≥ 9 with minor bleeding</p>
<ul>
<li>
<p>stop</p>
</li>
<li>
<p>vit k 1-5mg</p>
</li>
<li>
<p>test daily</p>
</li>
<li>
<p>restart warfarin</p>
</li>
</ul>
</li>
<li>
<p>major bleeding</p>
<ul>
<li>
<p>stop</p>
</li>
<li>
<p>vit k 10mg slow IV</p>
</li>
<li>
<p>refer for factor replacement</p>
</li>
</ul>
</li>
</ul>
<h3 id="dabigatran">Dabigatran</h3>
<h4 id="indications">Indications</h4>
<ul>
<li>
<p>prevention of stroke in non-valvular atrial fibrillation</p>
<ul>
<li>
<p>requires at least one other risk factor</p>
<ul>
<li>
<p>previous TIA/Stroke</p>
</li>
<li>
<p>LVEF \&lt; 40%</p>
</li>
<li>
<p>symptomatic heart failure</p>
</li>
<li>
<p>age ≥ 75uo</p>
</li>
<li>
<p>age ≥ 65 + DM or HTN or CAD</p>
</li>
</ul>
</li>
<li>
<p>NOT indicated valvular heart disease or mechanical heart valves</p>
</li>
<li>
<p>NOT been evaluated with bioprosthetic valves</p>
</li>
</ul>
</li>
<li>
<p>VTE prophlaxis after major orthopaedic surgery</p>
</li>
<li>
<p>(treatment of VTE)</p>
</li>
<li>
<p>contraindicated with ketoconazole</p>
</li>
</ul>
<h4 id="dosing">Dosing</h4>
<ul>
<li>
<p>150mg bd provided CrCl >30mL/min</p>
</li>
<li>
<p>110mg bd aged ≥ 80yo</p>
</li>
<li>
<p>aged 75-80 with CrCl 30-50 consider 110mg bd: if risk of bleeding high and risk of thrombosis low</p>
</li>
<li>
<p>for VTE prophlaxis</p>
<ul>
<li>
<p>220mg OD CrCl >50</p>
</li>
<li>
<p>150mg OD Cr 30-50</p>
</li>
</ul>
</li>
</ul>
<h4 id="advantages-over-warfarin">advantages over warfarin</h4>
<ul>
<li>
<p>more convient</p>
</li>
<li>
<p>effective anti-coagulation in those who previously difficult to ontrol on warfarin</p>
<ul>
<li>assuming adherence good</li>
</ul>
</li>
<li>
<p>fewer drug and dietary interactions than warfarin</p>
</li>
<li>
<p>reduction in risk of intracranial haemorrhage</p>
</li>
</ul>
<h4 id="initiating">initiating</h4>
<ul>
<li>
<p>all patients should have assessment of renal function</p>
<ul>
<li>CI in CrCl\&lt;30</li>
</ul>
</li>
<li>
<p>if already anti-coagulated</p>
<ul>
<li>
<p>warfarin stopped</p>
</li>
<li>
<p>started when INR \&lt;2</p>
</li>
</ul>
</li>
<li>
<p>Change back - warfarin</p>
<ul>
<li>
<p>check CrCl</p>
<ul>
<li>
<p>if >50mL/min warfarin started 3 days prior before discontinuing dabigatran</p>
</li>
<li>
<p>if 30-50mL intiiate warfarin 2 days before stopping dabigatran</p>
</li>
</ul>
</li>
</ul>
</li>
<li>
<p>stopping prior to planned surgical procedure</p>
<ul>
<li>
<p>CrCl >50</p>
<ul>
<li>
<p>24hours prior</p>
</li>
<li>
<p>or 48hrs if high risk of bleeding/major</p>
</li>
</ul>
</li>
<li>
<p>30-50</p>
<ul>
<li>2-4 days - action prolonged</li>
</ul>
</li>
</ul>
</li>
</ul>
<h4 id="monitoring_1">Monitoring</h4>
<ul>
<li>
<p>renal function</p>
<ul>
<li>
<p>initiation</p>
</li>
<li>
<p>change in clincial situation</p>
</li>
<li>
<p>annually >75</p>
</li>
<li>
<p>annually (but pref 3-6mo) cr cl 30-50</p>
</li>
</ul>
</li>
<li>
<p>wide therapeutic window, predictable pharmacokinetics and pharmacodynamic</p>
</li>
<li>
<p>rapid onset of action</p>
</li>
<li>
<p>if bleeding</p>
<ul>
<li>
<p>stop</p>
<ul>
<li>
<p>Thrombin time</p>
</li>
<li>
<p>activated partial thromboplastin time</p>
</li>
<li>
<p>fibrinogen</p>
</li>
<li>
<p>ecarin clotting time</p>
</li>
</ul>
</li>
</ul>
</li>
</ul>
<h4 id="adverse-effects">Adverse effects</h4>
<ul>
<li>
<p>non-haemorrhagic GI adverse effects = most frequent</p>
<ul>
<li>
<p>dyspepsia</p>
<ul>
<li>
<p>treat with PPI</p>
<ul>
<li>not significant interaction</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
<li>
<p>bleeding</p>
<ul>
<li>
<p>can be minimised</p>
<ul>
<li>
<p>correct dose</p>
</li>
<li>
<p>inr \&lt;2 on initiation</p>
</li>
<li>
<p>used in caution with other medicines that increase bleeding</p>
</li>
<li></li>
</ul>
</li>
</ul>
</li>
</ul>
      </div>
    </div>

  </div>
    

    <div class="footer">
        <p>Website powered by <a href="http://urubu.jandecaluwe.com">Urubu</a></p>
    </div>


</div> 


    <!-- jQuery (necessary for Bootstrap's JavaScript plugins) -->
    <script src="https://code.jquery.com/jquery.js"></script>
    <!-- Include all compiled plugins (below), or include individual files as needed -->
    <script src="//netdna.bootstrapcdn.com/bootstrap/3.2.0/js/bootstrap.min.js"></script>

  </body>
</html>
